6/6 Together, their projects hold the key to advance in vivo immunotherapies. Stay in touch and learn about the work of our brilliant PhD students!.

5/6 His project will expand our combinatorial barcoded transcription factor screening platform for reprogramming a repertoire of immune cells and advance precision immunotherapy.

4/6 Daniel will develop his project “A combinatorial transcription factor screening platform for immune cell reprogramming” in articulation with IRB Barcelona, harnessing their expertise in single-cell transcriptomics and lineage tracing.

3/6 Her project will focus on in vivo reprogramming of hematopoietic stem cells through the overexpression of GATA2, FOS, and GFI1B to promote rejuvenation of the immune system, whose function declines with aging.

2/6 Margarida will develop her PhD on the topic: “Unraveling the potential of hemogenic reprogramming for immune rejuvenation in aging” in articulation with the University of Lausanne, with in-depth knowledge about aging and in vivo cell reprogramming.

1/6 Congrats to Margarida Brás and Daniel Oliveira that were awarded with PhD studentships from the Foundation for Science and Technology (FCT) @fct_pt.

@ervin_ascic 3/3 For more, go here: Share with us your insights on the utility of step-by-step instructive papers in the field of cancer immunotherapy!.

2/3 First-authored by our PhD students @ervin_ascic and Gaia Fontanari, this method offers a tool to apply our technology of in vivo cDC1 reprogramming, understand cDC1-mediated anti-tumor immunity, and track changes within the tumor microenvironment!.

1/3 Our most recent protocol paper, “Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells”, is out in JoVE! @JoVEJournal

Their work expands our possibilities to develop immune cell reprogramming for immunotherapy, introducing new cell types into our cards. Stay with us, as we’ll soon show their findings. Congrats Dr. Inês and Dr. Luís!🎊.

Doubly proud! 🎉.@inesncaiado and @luisfholiveira defended their PhDs this month with a big audience of cell reprogrammers. They brilliantly discussed their great contributions to the future of the field.

3/3 HALRIC pilot projects aim to strengthen the Life Sciences sector in Northern Europe. This project will harness Cryo-EM (from Lund University and SciLifeLab) to inform chromatin dynamics during reprogramming and guide the design of synthetic approaches. Well done!✨.

2/3 Sandhya’s project “Decoding Transcription Factor Cooperativity: Structural basis of PU.1, IRF8, and BATF3-mediated chromatin remodeling in cDC1 reprogramming” will uncover how PU.1, IRF8, and BATF3 interact with nucleosomes to activate an immune response.

1/3 Glad to share that the work of our Postdoctoral Fellow Sandhya Malla @mal71056 secured funding from the Hanseatic Life Science Research Infrastructure Consortium (HALRIC) to study the mechanisms of dendritic cell reprogramming!

3/3 Hugo will advance a strategy to reprogram autoreactive T-cells into Tregs capable of inducing antigen-specific immune tolerance without broadly suppressing the immune system. Well done, Hugo, a great adventure lies ahead! .For more info see:

2/3 Regulatory T-cells (Tregs) suppress aberrant self-reactive immune responses, a function impaired in autoimmune diseases. Current autoimmunity treatments often lead to off-target effects. What if we could generate functional Tregs directly in target tissues?.

1/3 Congrats to our team member Hugo Couto Moreira, who was awarded a Doctoral INPhINIT Retaining Fellowship from “la Caixa” Foundation to develop his PhD project “Reprogramming Regulatory T-cells”! @FundlaCaixa

Our project includes the collaboration of Dr. Inge Marie Svane (Herlev Hospital) and Dr. Joan Yuan (Lund University). To know more about this innovation in cancer immunotherapy, go here: #CRI-CLIP #Immunotherapy.

The CRI CLIP grant will improve our knowledge of tertiary lymphoid structure (TLS) formation & advance novel cancer immunotherapy, merging in vivo dendritic cell reprogramming and engineering of synthetic TLS. This can transform treatment responses for immune-resistant melanomas!.

It’s an honor to share that our lab was awarded a Clinic & Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (CRI) for the project “Engineering Synthetic Tertiary Lymphoid Structures in Melanoma with Dendritic Cell Reprogramming”. @CancerResearch